Acetazolamide use while Breastfeeding
Drugs containing Acetazolamide: Diamox, Diamox Sequels
Acetazolamide Levels and Effects while Breastfeeding
Summary of Use during Lactation
Limited information indicates that maternal doses of acetazolamide up to 1000 mg daily produce low levels in milk and would not be expected to cause any adverse effects in breastfed infants.
Maternal Levels. A woman who was 6 days postpartum was given a sustained-release acetazolamide (Diamox Sequels) 500 mg twice daily by mouth for increased intraocular pressure. Milk acetazolamide levels ranged from 1.3 to 2.1 mg/L from 1 to 9 hours after the dose. The authors estimated that the infant received a daily dose of 0.6 mg, which was less than 0.7% of the maternal weight-adjusted dosage.
Infant Levels.A 10-day old breastfed (extent not stated) infant whose mother was taking sustained-release acetazolamide (Diamox Sequels) 500 mg twice daily from day 6 postpartum. The infant's acetazolamide plasma levels were 0.2, 0.6 and 0.2 mg/L at 2, 3.5 and 12 hours after the maternal dose. These levels averaged 1.5% of 3 maternal plasma levels taken on the same day.
Effects in Breastfed Infants
A breastfed (extent not stated) infant whose mother was taking sustained-release acetazolamide (Diamox Sequels) 500 mg twice daily exhibited no apparent adverse effects related to acetazolamide from day 6 to day 10 postpartum.
A mother who was taking acetazolamide 250 mg orally twice daily as well as using 2 drops of timolol 0.5% eye drops daily and pilocarpine eye drops twice daily delivered a preterm infant at 36 weeks of gestation. The infant began 5 months of exclusive breastfeeding at 6 hours after birth. On day 2, the infant developed electrolyte abnormalities consisting of hypocalcemia, hypomagnesemia, and metabolic acidosis. The infant was treated with oral calcium gluconate and a single dose of intramuscular magnesium sulfate. Despite continued breastfeeding and maternal drug therapy, the infant's mild metabolic acidosis disappeared on day 4 of life and the infant was gaining weight normally at 1, 3 and 8 months, but had mild hypotonicity. The authors considered the metabolic effects to be caused by transplacental passage of acetazolamide that resolved despite the infant being breastfed. The infant gained weight adequately during breastfeeding, but had some mild, residual hypertonicity of the lower limbs requiring physical therapy.
1. Soderman P, Hartvig P, Fagerlund C. Acetazolamide excretion into human breast milk. Br J Clin Pharmacol. 1984;17:599-600. Letter. PMID: 6733009
2. Merlob P, Litwin A, Mor N. Possible association between acetazolamide administration during pregnancy and metabolic disorders in the newborn. Eur J Obstet Gynecol Reprod Biol. 1990;35:85-8. PMID: 2311821
3. Bedrosian L, Erzurumlu K, Levine LS. Acetazolamide (Diamox) in the inhibition of postpartum breast engorgement. N Y State J Med. 1957;57:3997-8. PMID: 13493780
CAS Registry Number
Carbonic Anhydrase Inhibitors
LactMed Record Number
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
More about acetazolamide
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 95 Reviews – Add your own review/rating
- Drug class: carbonic anhydrase inhibitor anticonvulsants